- PMLiVE

Environment: where does the pharmaceutical industry stand?

Industry is taking environmental commitments more seriously, especially after pivotal events such as COP26 and publication of the IPCC’s cautionary ‘now or never’ report.Pharma is no exception, with some of...

- PMLiVE

That ‘don’t’ impress me much

I am going to come straight out with it – when it comes to evaluation, I am not impressed by impressions.By the time you are reading this, many of you...

- PMLiVE

How the Royal Society’s EiR programme can help to drive UK innovation

Earlier this year I attended a meeting of the latest cohort of Entrepreneurs in Residence (EiR) at the Royal Society, the UK’s national academy of sciences.I was struck by the...

- PMLiVE

My body. My choice. Are we all talking about the same thing?

By now you have all heard. In fact, the world has heard. The US Supreme Court has overturned Roe v Wade. The constitutional right to abortion in the US no...

- PMLiVE

Strategic commitment

Life sciences businesses, such as pharmaceuticals and medical technology, are characterised by a high proportion of educated people in roles that have high discretion. That is, you can’t tell them...

- PMLiVE

Achieving communication excellence by targeting the right channel at the right time

By Danny Buckland

- PMLiVE

A creative awakening – how pharma is bringing innovation to the patient journey

By Danny Buckland

- PMLiVE

Your new goal for communications – social impact

By Chris Bath

- PMLiVE

Asking better questions to inform a stronger strategy

Pausing to question the data being used to inform decisions is invaluable in creating better strategy

- PMLiVE

Walking in their shoes

The impact of experiencing what it would be like to have a chronic disease for a day

- PMLiVE

Will that be cash or charge?

India is asking people to pay for booster shots, but extremely poor countries should never consider charging people for public health services

- PMLiVE

Eli Lilly and Incyte’s Olumiant receives FDA approval for alopecia

The treatment is the first and only systemic medicine for adults with the condition

- PMLiVE

The future of healthcare professional engagement

By Ilana Scholl

- PMLiVE

Lessons from a pandemic – holistic strategy in the time of coronavirus

COVID-19 has delivered a scenario where developing the strategy for any brand is a challenge

- PMLiVE

Using consensus to drive clarity

By Derek Annan